Jefferies Financial Group Inc. Invests $2.33 Million in Xeris Biopharma Holdings, Inc. $XERS

Jefferies Financial Group Inc. acquired a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 293,670 shares of the company’s stock, valued at approximately $2,326,000.

Other institutional investors also recently bought and sold shares of the company. Kestra Advisory Services LLC bought a new stake in Xeris Biopharma during the 4th quarter valued at $25,000. Allworth Financial LP bought a new position in shares of Xeris Biopharma in the 2nd quarter worth $34,000. KBC Group NV bought a new position in shares of Xeris Biopharma in the 1st quarter worth $27,000. State of Wyoming purchased a new stake in shares of Xeris Biopharma during the 2nd quarter worth $52,000. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Xeris Biopharma by 9,276.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after purchasing an additional 7,421 shares during the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Xeris Biopharma

In other Xeris Biopharma news, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $97,440.00. Following the completion of the transaction, the director owned 126,500 shares of the company’s stock, valued at approximately $770,385. This trade represents a 11.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $8.50, for a total value of $42,500.00. Following the completion of the transaction, the insider directly owned 1,361,053 shares in the company, valued at approximately $11,568,950.50. The trade was a 0.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 271,499 shares of company stock valued at $2,038,917. Insiders own 4.35% of the company’s stock.

Analyst Upgrades and Downgrades

XERS has been the topic of several analyst reports. Wall Street Zen lowered Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Barclays raised their price target on shares of Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $12.00.

Xeris Biopharma Stock Performance

Shares of XERS opened at $8.48 on Friday. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The firm has a market cap of $1.55 billion, a PE ratio of -77.09 and a beta of 0.66. Xeris Biopharma Holdings, Inc. has a 12 month low of $5.25 and a 12 month high of $10.08. The stock has a fifty day moving average price of $8.29 and a 200-day moving average price of $6.93.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The business had revenue of $92.10 million for the quarter, compared to analysts’ expectations of $90.12 million. Equities research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.